Inoperable recurrent rectal cancer: results of a prospective trial with radiation therapy and razoxane.
OBJECTIVE
The effect of the sensitizer razoxane was prospectively evaluated in recurrent rectal cancer. Endpoints of the study were mainly local response rates and survival.


METHODS
From 1984 to 1990 razoxane was given together with radiation therapy to 40 patients with recurrent inoperable rectal cancer. Loco-regional relapses in the pelvis were isolated in 24 and associated with distant metastases in 16 patients. Special attention was given to the subset of 24 patients with isolated local recurrences. This group was compared with historical controls treated with radiotherapy alone. The dosage of razoxane was 150 mg/m2 daily orally starting 5 days before the first irradiation. The drug was then given each radiation day until the end of treatment. The median radiation dose was 60 (40-62) Gy in the evaluable patients. The minimum follow-up was 32 months and the median 72 months.


RESULTS
The rates of complete plus partial responses were 57% and 54%, respectively, for recurrent patients without and with distant metastasis. The 23 evaluable patients with isolated local relapses had a median survival of 24 months (12-94+); all patients surviving at least 1 year.


CONCLUSIONS
The combination of radiotherapy and razoxane may lead to better local control and improved median survival compared to our historical controls and literature reports where radiotherapy alone was used. The treatment is easy to administer and is associated with a moderate toxicity.
Rhomberg
W
W
Department of Radiooncology, Landeskrankenhaus Feldkirch, Austria.
Eiter
H
H
Hergan
K
K
Schneider
B
B
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy*; D010166:Palliative Care; D011446:Prospective Studies; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*; D011878:Radiotherapy / Q000009:adverse effects; D011929:Razoxane / Q000494:pharmacology*; D012004:Rectal Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D015996:Survival Rate
D011838:Radiation-Sensitizing Agents; D011929:Razoxane